Track topics on Twitter Track topics that are important to you
Schizophrenia drug Abilify MyCite becomes the first drug approved in the U.S. with a sensor that digitally tracks if patients have ingested their medication. The U.S. Food and Drug Administration on Monday approved Abilify MyCite (aripiprazole tablets with sensor), developed by Otsuka Pharmaceutical Co., Ltd. In Japan, Otsuka Holdings' shares were gaining around 2.7 percent
Original Article: FDA Approves Pill With Sensor Abilify MyCite; Otsuka Stock UpNEXT ARTICLE
Schizophrenia is a common serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...